Primary Job Title Board of Directors Primary Organization 
Eidogen-Sertanty
Gender Male
Investor Type
Christopher Fuglesang, Ph.D., J.D., joined Tavistock Life Sciences in 2005 and is responsible for co-managing the group's public market activities, including identifying investment opportunities involving new drugs and medical devices, clinical and regulatory strategies, capital structuring, partnering, merger and acquisition strategies as
well as intellectual property strategies.
In this role, Dr. Fuglesang has handled and supervised a variety of public business transactions, including public offerings, mergers and acquisitions, joint ventures and other strategic collaborations and commercial transactions in the healthcare space. Dr. Fuglesang brings with him years of experience in building and developing life science companies, previously founding as well as holding executive management positions at various biotech companies. His responsibilities in these positions included intellectual property management, licensing and corporate development.
Currently, Dr. Fuglesang is a member of the board of directors at Ambrx, Kalypsys. And Eidogen-Sertany.
Dr. Fuglesang holds a doctorate in chemical physics from the University of California, Los Angeles, a juris doctor from the Boston University School of Law and bachelor's degrees in both chemistry and physics from the University of California, Los Angeles.
